Houlihan Lokey Down 21% YTD: Buy the Dip or Stay Cautious?

Houlihan Lokey shares are down 21.3% year to date, versus a 5.7% industry decline, amid two disappointing quarters and weaker advisory activity. Current-year EPS consensus is $6.93, down 8.3% year over year after four downward revisions in 60 days, while revenue is projected to decline 0.3% to $2.61 billion. Corporate Finance revenue fell 24% to $303 million, technology-related revenue dropped about 54% ($53 million), and restructuring revenue also weakened, although record Corporate Finance backlog could support a later recovery. With a Zacks Rank #5 Strong Sell and forward P/E of 17.48x versus the industry's 16.94x, the article views near-term risk-reward as unfavorable.

Analysis

HLI's problem is not simply lower advisory activity; it is adverse fee mix at a fixed-cost professional-services platform. Flat transaction counts alongside lower realization imply that even a modest recovery in closed mandates may not restore margins unless larger assignments return, while senior-hiring and acquisition spending raises operating leverage risk. The key read-through is that backlog is only valuable when conversion timing and fee size are visible; management's pipeline commentary should receive a discount until revenue per transaction stabilizes.

PJT is the cleaner relative beneficiary if restructuring activity broadens, given its premium multiple already prices superior execution and its recent relative strength can attract incremental long-only flows. EVR offers the more defensive valuation hedge within independent advisory, but its own stock weakness means a sector-wide M&A recovery could narrow the HLI discount before HLI fundamentals improve. Large-bank advisory franchises, including GS and JPM, are second-order share-gain candidates if clients increasingly value financing certainty alongside advice.

Over the next 1-3 months, HLI needs evidence of fee realization rather than another record-pipeline claim: Corporate Finance revenue per close, technology fee recovery, and restructuring mandate conversion are the relevant catalysts. A further guidance reset or another quarter of weak conversion would likely compress HLI toward or below peer valuation; conversely, two quarters of higher average fees could drive a rapid rerating because the stock has already underperformed. The contrarian point is that a broad credit deterioration would help restructuring, but that is not automatically bullish for HLI if it also delays its higher-fee M&A pipeline and creates execution costs from continued expansion.

Key Decisions for Investors

• Maintain/establish a 3-6 month pair: long PJT / short HLI, sized beta-neutral. The trade isolates superior advisory/restructuring execution from HLI's fee-conversion risk; target 10-15% relative outperformance, with a stop if HLI reports two consecutive quarters of improving revenue per transaction and raises full-year margin expectations.
• For less factor risk, short HLI versus long EVR over the next earnings cycle. EVR's lower relative valuation provides downside cushion, while HLI remains vulnerable to another estimate reset; cover the short if HLI's Corporate Finance revenue growth turns positive with average fees improving, not merely transaction count.
• Do not add outright HLI exposure ahead of results. Revisit only after verifiable evidence that larger mandates are closing—specifically sequential improvement in Corporate Finance revenue per transaction and technology advisory revenue—with management maintaining rather than expanding compensation and hiring intensity.
• Watch HY spreads and leveraged-loan default activity as a 6-18 month restructuring trigger. If spreads widen materially while HLI's restructuring transaction count begins rising, close the HLI short: the embedded countercyclical earnings option could become more valuable than current estimates imply.